Pharmafile Logo
Pharmafocus logo
Advanced Search

Angiex’s IND application for AGX101 cleared by FDA

November 3, 2023
Medical Communications AGX101, Angiex, FDA, Oncology

Angiex has announced that the US Food and Drug Administration has cleared its Investigational New Drug (IND) application for AGX101, …

News

FDA approves Phathom Pharmaceuticals’ Voquezna for erosive GERD

November 3, 2023
Medical Communications Erosive GERD, FDA, Gastrointestinal tract, Phathom Pharmaceuticals, Voquezna

Phathom Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) tablets 10mg and 20mg, …

News

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

November 2, 2023
Medical Communications Arrowhead Pharmaceuticals, GSK, Infections and infestations, Janssen, hepatitis B

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen Pharmaceuticals, a Johnson & Johnson …

News

Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap

November 2, 2023
Business Services AbbVie, Aldeyra Therapeutics, Opthalmology, reproxalap

Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement for the license to develop, …

News

ViroCell and GOSH gain MHRA manufacturing approval

November 1, 2023
Manufacturing and Production Great Ormand Street Hospital, MHRA, Pharmacy, ViroCell, manufacturing, viral vectors

ViroCell Biologics has announced that it can now manufacture and export viral vectors from Great Ormand Street Hospital’s (GOSH) state-of-the-art …

News

AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development

November 1, 2023
Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine

AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …

News

Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

October 31, 2023
Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …

News

NMPA approves CStone’s Cejemly for lymphoma treatment

October 31, 2023
Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma

CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …

News

First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China

October 30, 2023
Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab

Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …

News

GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment

October 30, 2023
Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …

News

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

October 27, 2023
Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …

News

Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment

October 27, 2023
Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …

News

China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment

October 26, 2023
Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria

ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai shares new data for Leqembi for Alzheimer’s treatment

October 26, 2023
Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …

News

FDA approves Servier Pharmaceuticals’ new MDS therapy

October 25, 2023
Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes

The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …

News

GSK shares new data for RSV vaccine Arexvy

October 25, 2023
Research and Development Arexvy, GSK, Immunology, RSV, Vaccine

GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …

News

AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA

October 24, 2023
Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA

AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …

News
glsun-mall-9xmv81sz5fw-unsplash

Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics

October 24, 2023
Business Services Kurma Partners, Pharmacy, Samsung BioLogics

Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …

News

Roche announces acquisition of Telavant

October 23, 2023
Business Services Gastrointestinal tract, Roche, Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …

News

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

October 23, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025